Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bliss GVS Pharma's Enterprise Value is ₹50,663 Mil.
Bliss GVS Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Bliss GVS Pharma's EV-to-FCF for today is .
The historical rank and industry rank for Bliss GVS Pharma's EV-to-FCF or its related term are showing as below:
BOM:506197'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 58.57
Current: 58.57
During the past 13 years, the highest EV-to-FCF of Bliss GVS Pharma was 58.57. The lowest was 0.00. And the median was 0.00.
BOM:506197's EV-to-FCF is ranked worse than 77.23% of 571
companies
in the Drug Manufacturers industry
Industry Median: 21.2
vs BOM:506197: 58.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bliss GVS Pharma's PE Ratio (TTM) for today is calculated as:
Bliss GVS Pharma's share price for today is ₹488.95.
Bliss GVS Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11.990.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bliss GVS Pharma EV-to-FCF Related Terms
Bliss GVS Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's EV-to-FCF falls into.
Bliss GVS Pharma's current Enterprise Value is ₹50,663 Mil.
Bliss GVS Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹488.95 is trading 221% above its estimated GF Value™ of ₹152.31.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
EV-to-FCF:
GF Value™: ₹152.31 vs. price of ₹488.95 (221% above fair value)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
57GF Score
Get the complete analysis for BOM:506197
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
